NCT03981705View on ClinicalTrials.gov

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

February 19, 2024

Study Completion Date

November 26, 2024

Conditions
TN ER-/PR-/HER2- Breast CancerTriple Negative Breast CancerHER2-positive Breast CancerERany/PRany/HER2+ Breast Cancer
Interventions
RADIATION

Standard Trimodality Breast Imaging

Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).

Trial Locations (1)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03981705 - Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer | Biotech Hunter | Biotech Hunter